LMR Partners’s Alaunos Therapeutics TCRT Stock Holding History

LMR Partners’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-665	Closed	-$171K	–	1269
2022 Q3	$171K	Hold	665	–	–	﹤0.01%	1025
2022 Q2	$124K	Buy	+665	New	+$63.6K	﹤0.01%	1091

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return

SGCA

Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

LMR Partners's TCRT Position: Q4 2022 in Review

LMR Partners sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 665 shares — an estimated $171K sold.

LMR Partners first reported a position in TCRT in Q2 2022 and held it in 2 quarters. The position peaked at $171K in Q3 2022. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

LMR Partners reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 665 Alaunos Therapeutics shares in Q4 2022, an estimated $171K.
LMR Partners first reported a position in Alaunos Therapeutics in Q2 2022 and held it in 2 quarters.
LMR Partners's Alaunos Therapeutics position peaked at $171K in Q3 2022.
122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.